WuXi Biologics and Aravive Collaborate to Develop Novel High-Affinity Bispecific Antibodies for Cancer and Fibrosis

 WuXi Biologics and Aravive Collaborate to Develop Novel High-Affinity Bispecific Antibodies for Cancer and Fibrosis

Wuxi Biologic; Acquire; Bayer; Production Facility; Germany

Shots:

  • The collaboration leverages WuXi’s WuXiBody platform to develop high-affinity bispecific Ab targeting CCN2 for the treatment of cancer and fibrosis
  • WuXi Biologics will be responsible for biologics discovery, process development, and manufacturing, whereas Aravive will be responsible for pre/ clinical development
  • In 2018, Aravive and WuXi Biologics expanded their manufacturing collaboration for development and manufacturing of AVB-500 following the US FDA’s IND filing of AVB-500

Click here to­ read full press release/ article | Ref: PRNewswire  | Image: Wuxi Biologics

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post